CA2556789A1 - Utilisation de beta-lapachone pour traiter des tumeurs hematologiques - Google Patents

Utilisation de beta-lapachone pour traiter des tumeurs hematologiques Download PDF

Info

Publication number
CA2556789A1
CA2556789A1 CA002556789A CA2556789A CA2556789A1 CA 2556789 A1 CA2556789 A1 CA 2556789A1 CA 002556789 A CA002556789 A CA 002556789A CA 2556789 A CA2556789 A CA 2556789A CA 2556789 A1 CA2556789 A1 CA 2556789A1
Authority
CA
Canada
Prior art keywords
lapachone
pharmaceutically acceptable
acceptable salt
cell
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002556789A
Other languages
English (en)
Inventor
Chiang J. Li
Youzhi Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arqule Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2556789A1 publication Critical patent/CA2556789A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)

Abstract

La présente invention fournit des procédés qui utilisent des agents efficaces dans le traitement de cancers hématologiques et d'affections précancéreuses de cancers hématologiques. De plus, la présente invention fournit des agents capables de servir d'inhibiteur de la prolifération des cellules dans des cellules hématologiques.
CA002556789A 2004-02-20 2005-02-18 Utilisation de beta-lapachone pour traiter des tumeurs hematologiques Abandoned CA2556789A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54591404P 2004-02-20 2004-02-20
US60/545,914 2004-02-20
PCT/US2005/005646 WO2005082357A1 (fr) 2004-02-20 2005-02-18 Utilisation de bêta-lapachone pour traiter des tumeurs hematologiques

Publications (1)

Publication Number Publication Date
CA2556789A1 true CA2556789A1 (fr) 2005-09-09

Family

ID=36168365

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002556789A Abandoned CA2556789A1 (fr) 2004-02-20 2005-02-18 Utilisation de beta-lapachone pour traiter des tumeurs hematologiques

Country Status (3)

Country Link
JP (1) JP2007523191A (fr)
CA (1) CA2556789A1 (fr)
WO (1) WO2005082357A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050187288A1 (en) * 2004-02-20 2005-08-25 Chiang Li Beta-lapachone and methods of treating cancer
US8614228B2 (en) 2004-08-11 2013-12-24 Arqule, Inc. Quinone prodrug compositions and methods of use
WO2006020722A2 (fr) * 2004-08-11 2006-02-23 Arqule, Inc. Compositions pharmaceutiques de beta-lapachone et d'analogues de beta-lapachone possedant un potentiel de ciblage de tumeur ameliore
US7790765B2 (en) 2007-04-30 2010-09-07 Arqule, Inc. Hydroxy sulfonate of quinone compounds and their uses
US20120142650A1 (en) * 2010-12-07 2012-06-07 John Hollingsworth Method for treating lung disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002058694A2 (fr) * 2000-11-07 2002-08-01 Dana-Farber Cancer Institute, Inc. Procede de traitement de tumeurs et de cancers hematologiques
CN1729183A (zh) * 2002-11-18 2006-02-01 阿奎利公司 新颖的拉帕酮化合物及其使用方法
AU2003293333A1 (en) * 2002-12-02 2004-06-23 Arqule, Inc. Method of treating cancers

Also Published As

Publication number Publication date
WO2005082357A1 (fr) 2005-09-09
JP2007523191A (ja) 2007-08-16
WO2005082357A8 (fr) 2006-04-20

Similar Documents

Publication Publication Date Title
US20080146584A1 (en) Method of treating cancers using beta-lapachone or analogs or derivatives thereof
US6214821B1 (en) Methods and composition for the inhibition of cancer cells
US20130237582A1 (en) Pharmaceutical combination of paclitaxel and a cdk inhibitor
Bashash et al. Anti-tumor activity of PI3K-δ inhibitor in hematologic malignant cells: shedding new light on resistance to Idelalisib
CA2556789A1 (fr) Utilisation de beta-lapachone pour traiter des tumeurs hematologiques
Ku et al. Phase II trial of sequential paclitaxel and 1 h infusion of bryostatin-1 in patients with advanced esophageal cancer
An et al. PDE3A inhibitor anagrelide activates death signaling pathway genes and synergizes with cell death-inducing cytokines to selectively inhibit cancer cell growth
EP1722776A2 (fr) Utilisation de beta-lapachone comme agent anti-cancereux a large spectre
EP1722775A1 (fr) Utilisation de beta-lapachone pour traiter des tumeurs hematologiques
US20050197405A1 (en) Treatment of hematologic tumors and cancers with beta-lapachone, a broad spectrum anti-cancer agent
EP2033638A2 (fr) Béta-lapachone pour le traitement du cancer pancréatique
CA2556759A1 (fr) Combinaisons de beta-lapachone et de medicament en phase s pour le traitement du cancer
US20050192360A1 (en) Method of treatment of pancreatic cancer
Gupta et al. In vitro synergism between LFA-1 targeting leukotoxin (Leukothera™) and standard chemotherapeutic agents in leukemia cells
Parekh et al. Circumvention of adriamycin resistance: effect of 2-methyl-1, 4-naphthoquinone (vitamin K3) on drug cytotoxicity in sensitive and MDR P388 leukemia cells
US20050197406A1 (en) Method of treatment of lung cancer
Liu et al. TCH-1030 targeting on topoisomerase I induces S-phase arrest, DNA fragmentation, and cell death of breast cancer cells
US20050192247A1 (en) Method of treating cancers
EP2033639A2 (fr) Béta-lapachone pour le traitement du cancer du colon
US20050222246A1 (en) Beta-lapachone is a broad spectrum anti-cancer agent
US20050192361A1 (en) Method of treatment of colon cancer
US10550130B2 (en) Benzo-thiazolo-imidazole compounds and uses thereof
Viladkar et al. In vitro Effects of Pentoxifylline and Doxorabicin on Cell Survival and DNA Damage in Sensitive and MDRP388 Leukemia Cells
ITRM20130312A1 (it) Estratto di cynara spp. e suoi usi.

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued
FZDE Discontinued

Effective date: 20091229